# Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent

> **NCT04933552** · — · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 867 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **OTHER:** Siponimod

## Key facts

- **NCT ID:** NCT04933552
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-15
- **Primary completion:** 2032-05-31
- **Final completion:** 2032-05-31
- **Target enrollment:** 867 (ESTIMATED)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04933552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04933552, "Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04933552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*